Company Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Traws Pharma, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-17 pm EDT			5-day change	1st Jan Change
0.6827 ^USD	-1.93%		-14.13%	-8.44%

Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ
Apr. 04	Traws Pharma, Inc. Announces Chief Executive Office Changes	CI

Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclibâs mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).

Number of employees: 18

USD in Million	2022	Weight	2023	Weight	Delta
Oncology Therapeutics 100.0 %	0	100.0 %	0	100.0 %	0.00%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	0	100.0 %	0.00%

Managers	Title	Age	Since
Steven Fruchtman PSD	President	73	15-01-18
Mark Guerin DFI	Director of Finance/CFO	55	13-08-31
Meena Arora CTO	Chief Tech/Sci/R&D Officer	-	23-10-23
Victor Moyo CTO	Chief Tech/Sci/R&D Officer	-	23-10-23
Matthew Parris CTO	Chief Tech/Sci/R&D Officer	-	18-07-31

Members of the board	Title	Age	Since
James Marino BRD	Director/Board Member	74	15-06-30
Jack Stover BRD	Director/Board Member	69	16-05-22
Mary Shoemaker BRD	Director/Board Member	63	20-03-31
Steven Fruchtman PSD	President	73	15-01-18
Trafford Clarke BRD	Director/Board Member	66	22-12-18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	25,301,009	20,518,488 ( 81.10 %)	0	81.10 %

Name	Equities	%	Valuation
Viriom, Inc. 7.833 %	1,645,100	7.833 %	2 M $
OrbiMed Advisors LLC 4.977 %	1,045,261	4.977 %	1 M $
Vanguard Global Advisers LLC 3.374 %	708,618	3.374 %	715 704 $
BlackRock Institutional Trust Co. NA 1.185 %	248,881	1.185 %	251 370 $
Werner Cautreels 0.9522 %	200,000	0.9522 %	202 000 $
Renaissance Technologies LLC 0.9467 %	198,841	0.9467 %	200 829 $
Geode Capital Management LLC 0.9182 %	192,858	0.9182 %	194 787 $
Robert Redfield 0.4642 %	97,500	0.4642 %	98 475 $
Charles Pauza 0.4642 %	97,500	0.4642 %	98 475 $
Two Sigma Advisers LP 0.3712 %	77,966	0.3712 %	78 746 $

Onconova Therapeutics, Inc.

12 Penns Trail

18940-3423, Newtown

+267 759 3680

http://www.onconova.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6827 USD

Average target price

8 USD

Spread / Average Target

+1,071.82%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
TRAWS PHARMA, INC.	-8.44%	14.4M
IQVIA HOLDINGS INC.	-1.78%	41.36B
LONZA GROUP AG	+44.93%	41.3B
MODERNA, INC.	+4.01%	39.61B
CELLTRION, INC.	-15.14%	25.62B
ICON PUBLIC LIMITED COMPANY	+3.16%	24.09B
ALNYLAM PHARMACEUTICALS, INC.	-24.08%	18.38B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B
MEDPACE HOLDINGS, INC.	+24.76%	11.85B
UNITED THERAPEUTICS CORPORATION	+7.01%	11.07B

Other Biotechnology & Medical Research